CLOSE
Science & Technology

by -
0 1203
James Wishart at the Laser Electron Accelerator Facility. Photo by Roger Stoutenburgh/Brookhaven National Laboratory

By Daniel Dunaief

Leave a bicycle out in the rain for a few weeks and the metal gears and chain will develop rust that reduces the value and usefulness of that once shiny vehicle.

Now, imagine what the inside of a nuclear reactor looks like after high temperatures and ionizing radiation collide with everything they hit.

Chemists at Brookhaven National Laboratory, working with their partners at Idaho National Laboratory, recently showed how reactors cooled by molten salts had less corrosion in the reactor metals.

Molten salt cooled reactors are “intrinsically safe,” said James Wishart, Distinguished Chemist at BNL and director of the Molten Salts in Extreme Environments Energy Frontier Research Center. “They are already molten so they can’t melt down.”

The advantages of molten salt reactors are evident in their safety and their economics. These reactors are also better for the environment and for non proliferation of nuclear material. 

That is in contrast to what happened in 2011 after a tsunami hit the Fukushima nuclear plant in Japan, which had a meltdown at three of the plant’s reactors.

Fukushima lost the ability to cool the reactors because the tsunami knocked out the generators. A water reactor type meltdown can’t occur with a molten salt reactor because the fuel is already liquid and the reactor materials contain it in that state.

Chromium studies

In recent research published in the journal Physical Chemistry Chemical Physics, Wishart and his collaborators described the radiation-induced reactors of two ions of chromium, chromium 2+ and chromium 3+.

“Chromium is frequently the easiest metal to corrode from an alloy,” Wishart explained.

When chromium has a positive charge of three, it could be particularly problematic for the structural integrity and performance of the reactor. Chromium with a positive charge of two, on the other hand, may not be as problematic or corrosive to the nuclear reactor materials. Molten salts, which have negative ions of chlorine, can reduce chromium to the less reactive version.

By using the Laser Electron Accelerator Facility (LEAF) and the two-million electron volt Van de Graaff accelerator, Wishart tested the rate and temperature dependencies of reactions of the two chromium ions with reactive species generated by radiation in molten salt.

The solvated electrons and dichloride radicals, both of which have a negative charge, change the oxidation state of chromium to the less corrosive Cr 2+.

Commercial applications

Molten salt reactor research started in the late 1940’s.

In 1972, the Atomic Energy Commission expressed reservations about some technology issues and suggested that the engineering development of large components, a better understanding of the behavior of fission products and adequate remote inspection and maintenance techniques would be needed before molten salt reactors would be suitable for development.

The molten salt reactors were also not high enough on the development priority ranking of the government to have assurance of the required sustained resource allocation, according to an International Atomic Energy Agency Report on the Status of Molten Salt Reactor Technology.

Currently, however, at least a dozen companies are working on generators cooled by molten salts, with some involving chloride and others using fluoride.

Texas Abilene Christian University is building one such reactor, which would be the first university-based molten salt research reactor. The interest in these types of reactors has been growing around the world.

“We are providing information to help [people working in applied areas] understand the chemical transformations that molten salt fuel will undergo due to radiation inside the reactor,” said Wishart.

Several companies, including Thorcon Power and Seaborg Technologies, are also working on designs that can be built into modular forms and shipped by barge wherever power is needed.

In addition to reducing the threat from a melt down, these molten salt reactors also operate at relatively low vapor pressures, which is a “huge benefit in safety and in engineering,” Wishart added.

Molten salts have much lower vapor pressures than water because they are held together by very strong Coulombic forces, which come from the attraction of oppositely-charged ions.

Next studies

While the molten salt reactors favor the creation of a less problematic ionization state of chromium, they also produce other side reactions.

“With time and the large amount of radiation within the reactor, side reactions can lead to permanent products,” Wishart explained.

Studies of molten salt corrosion show a correlation between the presence and quantity of air and water and the rate of corrosion. Salts with low water and air contamination show little corrosion.

Wishart is now looking at more complex salt mixtures than the first series of experiments. Different cations, or positively charged ions, affect the reactivity of solvated electrons. He is investigating how that might divert the electron into side reactions that lead to the accumulation of permanent products.

Ground floor

Wishart was responsible for the construction of LEAF and for its operation for most of its 26-year history. When he and his colleagues were building the facility, he was eager to test out the facility’s ability to follow reactions on fast time scales, at about 10 picoseconds. A picosecond is such a small unit of time that an eye blink, which lasts about 0.1 seconds, is about 100 million picoseconds, so it records reactions rapid reactions.

Wishart was pleasantly surprised by all the scientific questions LEAF could address.

“I only started working on ionic liquids three years after LEAF was completed, so we could not anticipate how LEAF would enable that science to grow and then see it translate into molten salts,” he explained.

Wishart has published 76 papers on the radiation chemistry and/or physical chemistry since he started working on them in 2001.

Originally from the Detroit area, he returns periodically to spend time with family.

Wishart’s interest in chemistry began when he was a photographer for the high school yearbook, which, at the time, was printed in black and white. He made prints using traditional silver-based emulsions and was interested in the chemistry that caused the images to form under development.

When he was a PhD student at Stanford, Wishart mainly studied the chemistry of ruthenium, which is a second-row transition metal in the same family as iron. He found ruthenium satisfying to work with because scientists can watch the colors change to indicate when a reaction is done.

by -
0 1162
Jeremy Borniger with Cecilia Pazzi, a student from the cancer neuroscience course. Photo courtesy of CSHL

By Daniel Dunaief

People battling cancer can sometimes live long after they and their doctors first start treating the disease. Even if and when their types of cancer don’t continue to threaten their lives in the same way, they can struggle with symptoms such as chronic fatigue, pain, and difficulty sleeping.

These ongoing symptoms, however, could be a remnant of the way the nervous system and cancer interact, as well as a byproduct of the treatment.

Cancer neuroscience uses “tools from both neuroscience and cancer to fundamentally understand how cancer influences the functioning on the nervous system” and how the nervous system can be used to affect cancer, explained Jeremy Borniger, Assistant Professor at Cold Spring Harbor Laboratory.

Indeed, the field of cancer neuroscience, which extends beyond the study and treatment of brain cancer, has been growing over the last six years, after researchers made important discoveries that suggest the possible role and target for treatment of neurons.

A group of student during one of the lab sessions. Photo courtesy of CSHL

To encourage cancer scientists to learn more about the principles and techniques of neuroscience and to bring neuroscientists up to speed with cancer research, Borniger and three other scientists coordinated the first two-week Methods in Cancer Neuroscience course at Cold Spring Harbor Laboratory last month.

Attended by 14 researchers from domestic and international institutions, the days often started early in the morning and lasted past 10 p.m. The course included lectures about the basic science as well as considerable lab work.

Course attendees, most of whom had a background in cancer biology but little background in neuroscience, appreciated the opportunity to learn from the lecturers and to build their networks.

“We were introduced to a wide variety of techniques from the leading experts in the field and got to listen to insightful lectures from the invited speakers,” said Irem Uppman, a graduate student at Uppsala University in Sweden.

Uppman was grateful for the opportunity to meet her fellow students and hopes to stay in touch throughout their careers.

“It was also very exciting to meet all the instructors and lecturers,” Uppman said. “The small size of the course allowed us to interact more intimately which is something we often can’t do in the setting of big conferences.”

Uppman, who has been a PhD candidate for three years and hopes to graduate in the next two years, is a tumor biologist by background and hopes to incorporate more cancer neuroscience in her future work.

Course origins

During another conference, Borniger recalled how a group of cancer neuroscientists were discussing the field. One of the speakers suggested the need for a workshop where students could learn techniques from both of these disciplines.

“I raised my hand and said, “Cold Spring Harbor does this all the time,” Borniger said.

The leadership at the lab, including CEO Bruce Stillman, were excited about the possibility and encouraged Borniger to help coordinate the course. After the lab publicized the conference, 67 prospective students submitted applications. The organizers had several marathon zoom sessions to review the applicants.

“We wanted a good spread of earlier career and later career students,” said Borniger.

It would have been possible to fill the course with students conducting research on brain cancer exclusively, but the organizers wanted a broader scientific representation.

Neurons and cancer

As electrically active tissue, neurons play important roles in healthy biology as well as with cancer.

“It’s not just another cell type in the tumor environment,” Borniger explained, adding that nerve cells connect tumors with the central nervous system, which governs all conscious and unconscious systems.

Historically, cancer neuroscience has had two major moments that helped push the field into the mainstream of scientific research.

In a couple of papers between 2010 to 2013, before anyone started using the term “cancer neuroscience,” scientists showed that getting rid of localized sympathetic nerves, which include the kinds of nerves that control the heart rate and blood pressure, can cause breast cancer and prostate cancers to stop growing. 

“Everyone assumed the nerves don’t really do anything,” Borniger said. They are “little tiny projections in the tumor. A lot of cancer biologists ignored it” in part because of a paper in the 1960’s that suggested tumor cells were not electrically coupled together. Scientists believed, prematurely and inaccurately, that electrochemical signaling didn’t play a role in cancer. 

Then, in 2019, three papers came out around the same time that demonstrated that tumors in the brain can form connections with neurons like normal neurons do. These cancerous cells can integrate with circuits and communicate with each other.

“The level of integration that these cancer cells have with your brain dictates how bad the cancer is,” Borniger said. “If you disconnect the cancer cells from the neurons in your brain, you can make cancer much easier to treat.”

Researchers and pharmaceutical companies are looking for ways to use drugs to slow or stop the cancers.

Some research efforts are trying to block the gap junctions which dramatically reduces the number of cancer cells that receive input.

In breast to brain cancer, scientists are looking to target NMDA receptors, while in brain cancer, they’re targeting AMPA receptors.

Researchers are hoping to repurpose drugs approved for other conditions, such as bipolar disorder or epilepsy.

Origin story

When Borniger was in graduate school at Ohio State University, he was interested in sleep and how sleep works. He had the opportunity to attend several lectures and talks to gather information and pursue research that interested him.

In one meeting, which he said he might have attended to get free food, oncology nurses were talking about the subjective experience of cancer patients. At the end of the talk, they shared a summary slide of the top complaints, which included fatigue, pain, sleep disruption, cognitive impairment and changes in appetite.

Borniger thought these were all neuroscience problems.

He immediately looked online to see if anyone had seen how a tumor influences these neurological processes.

When he tested to see if breast cancer could influence brain activity and lead to sleep disruption, what he found convinced him it was a research field worth pursuing.

“The signal that comes from the tumor can reprogram your brain,” he said. “How does that work? That got me into the field.”

When he got the job at CSHL in 2019, Borniger attended a Banbury conference where the top people in the developing field gathered. He’s also interested in the opportunity to contribute to a new field.

“There’s not 30 years of dogma that we’re going to have to break down,” Borniger said. “We’re inventing the foundation as we go.”

Borniger is hoping to continue to expand the field to newer people, including those who work in neurodevelopment, bioinformatics and behavioral science. 

The tide is turning towards cancer neuroscience, Borniger believes. Years ago, cancer biologists would say, “Who cares about sleep? We’re driving to cure the cancer!” Now, with help from patient advocates, Borniger explained, clinicians are starting to realize the subjective health of the patient can have “immense impact” on their prognosis.

by -
0 1563
Pixabay photo

By Frank Artusa

For as long as there have been nation states, spies have been hard at work trying to gather intelligence for strategic advantage. Historically, the direct victims of such efforts have been government agencies, the military and corporate intellectual property, but recent events have put us all in the crosshairs when it comes to our digital communications.

Though sophisticated methods like collecting radio frequency emanations, tapping above ground and undersea communications cables, and other signals intelligence techniques, have been historically employed by adversary nations, few could have predicted the massive data breach recently perpetrated by an elite hacker group attributed to the People’s Republic of China called Salt Typhoon.

Salt Typhoon, a codename assigned by Microsoft’s cyber threat intelligence team, was first discovered in Fall 2024 to have compromised telecommunications systems and networks belonging to Verizon, T-Mobile, Spectrum and several others. The widespread compromise involved the exposure of data associated with phone calls, voicemails, and text messages impacting millions of Americans. The true extent of this massive breach has yet to be revealed, and it’s unknown whether the affected systems have been fixed.

The idea that any hacker group could obtain access to such critical infrastructure and persist, undetected, for apparently up to a year or more, is difficult to comprehend. The Federal Government’s Cybersecurity and Infrastructure Security Agency (CISA) indicated that Salt Typhoon was able to obtain access due to unpatched network hardware and leveraging entry points designed for use  by law enforcement, or “backdoors”.

Some experts blame the Communications Assistance for Law Enforcement Act (CALEA), a 1994 digital wiretapping law that compels telecommunications companies to assist law enforcement in conducting electronic surveillance with a court order. This tool by the very nature of its existence presents a potential backdoor into the telecom’s network. However, federal, state, and local law enforcement authorities utilize this technique to investigate criminal activity, with probable cause, to uncover evidence of crimes ranging from gang activity, organized crime, public corruption and everything in between. This makes CALEA a double edged sword: supporters laud its criticality to criminal investigations and detractors argue for its potential misuse by hackers or a corrupt government. 

Despite the obstacle described above, in December 2024 the FBI and CISA took the bold step of recommending that individuals utilize communication apps that offer end to end encryption (E2EE). E2EE is an encryption methodology that is used by apps like Whatsapp, Signal, and iMessage (when communicating between apple devices). 

E2EE makes it impossible for an interloper to read data due the advanced encryption utilized to encode data. As an example, it would require thousands, if not millions of years for a supercomputer to break encryption implemented by these applications. Quantum computing, a radical new computer processing technology poses a threat, but this innovation is still years away and governments are aggressively working to develop quantum proof encryption as well.

A clear use of the government’s own utilization of this E2EE technology was recently demonstrated when U.S. national security and defense officials used Signal to communicate tactical war plans in Yemen, albeit with unintended recipients.

Threats posed by advanced nation states capable of funding top tier cyber espionage operations is growing, with dozens of capable groups originating from Russia, Iran and North Korea as well as China. Additionally, this doesn’t include independent cyber criminal groups looking to steal and sell personal data. Considering the wide array of potential threats to digital data, E2EE appears to be one of the few tools guaranteed to stop hackers from eavesdropping on digital communications.

Internet Crime Complaint Center — www.ic3.gov

Frank Artusa, a resident of Smithtown, is a current cybersecurity professional and retired FBI Special Agent.

by -
0 650
METRO photo

By Daniel Dunaief

In the typical process of developing cures for medical problems or diseases, researchers explore the processes and causes and then spend years searching for remedies.

Ke Jian Liu. Photo by Jeanne Neville, Stony Brook Medicine

Sometimes, however, the time frame for finding a solution is cut much shorter, particularly when the Food and Drug Administration has already approved a drug treatment for another problem.

This could be the case for hemorrhagic stroke. Caused by a burst blood vessel that leads to bleeding in the brain, hemorrhagic stroke represents 13 percent of stroke cases, but accounts for 50 percent of stroke fatalities.

That’s because no current treatment exists to stop a process that can lead to cognitive dysfunction or death.

A researcher with a background in cancer and stroke, Ke Jian “Jim” Liu, Professor of Pathology and Associate Director or Basic Science at the Stony Brook Cancer Center who joined Stony Brook University in 2022, has found a mechanism that could make a hemorrhagic stroke so damaging.

When a blood vessel in the brain bursts, protoporphyrin, a compound that attaches to iron to form the oxygen carrying heme in the blood, partners up with zinc, a similar metal that’s in the brain and is released from neurons during a stroke. This combination, appropriately called zinc protoporphyrin, or ZnPP, doesn’t do much under normal conditions, but could be “highly toxic” in hypoxic, or low-oxygen conditions.

“We have done some preliminary studies using cellular and animal stroke models,” said Liu. “We have demonstrated on a small scale” that their hypothesis about the impact of ZnPP and the potential use of an inhibitor for the enzyme that creates it ‘is true.’”

These scientists recently received a $2.6 million grant over five years from National Institute of Neurological Disorders and Stroke, which is a branch of the National Institutes of Health.

Focusing on a key enzyme

After Liu and his colleagues hypothesized that the ZnPP was toxic in a low-oxygen environment, they honed in on ways to reduce its production. Specifically, they targeted ferrochelatase, the enzyme that typically brings iron and protoporphyrin together.

Iron isn’t as available in this compromised condition because it has a positive charge of three, instead of the usual plus two.

Liu discovered the role of zinc in research he published several years ago.

When a hemorrhagic stroke occurs, it creates a “perfect storm,” as the enzyme favors creating a toxic chemical instead of its usual oxygen carrying heme, Liu said. He is still exploring what makes ZnPP toxic.

The group, which includes former colleagues of Liu’s from the University of New Mexico, will continue to explore whether ZnPP and the enzyme ferrochelatase becomes an effective treatment target.

Liu was particularly pleased that currently approved treatments for cancer could be repurposed to protect brain cells during a hemorrhagic stroke. Indeed, with over 80 approved protein kinase inhibitors, which could work to stop the formation of ZnPP during a stroke, Liu and his colleagues have plenty of potential treatment options.

“We’re in a unique position that a clinically available drug that’s FDA approved for cancer treatment” could become a therapeutic solution for a potentially fatal stroke, Liu said.

To be sure, Liu and his colleagues plan to continue to conduct research to confirm that this process works as they suggest and that this possible therapy is also effective.

As with other scientific studies of medical conditions, promising results with animal models or in a lab require further studies and validation before a doctor can offer it to patients.

“This is an animal model, based on a few observations,” said Liu. “Everything needs to be done statistically.”

At this point, Liu is encouraged by these preliminary studies as the subjects that received an inhibitor are “running around,” he said. “You can see the difference with your own eyes. We’re excited to see that.”

Earlier hypotheses for what caused damage during hemorrhagic stroke focused on the release of iron. In research studies, however, using a chelator to bind to iron ions has produced some benefits, but they are small compared to the damage from the stroke. The chelator is “not really making any major difference,” said Liu.

The Stony Brook researcher did an experiment where he compared ZnPP with the damage from other metabolic products.

“ZnPP is several times more toxic than all the other things combined,” which is what makes them believe that ZnPP might be responsible for the damage, he said.

Proof of principle

For the purpose of the grant, Liu said the scientists were focusing on gathering more concrete evidence to support their theory. The researchers are also testing a few of the protein kinase inhibitors to demonstrate that they work.

In their preliminary studies, they chose several inhibitors based on whether the drug penetrates the blood brain barrier and that have a relatively high affinity for ferrochelatase.

“This opens the door for a new phase of the study,” Liu said. “Can we find the best drug that provides the best outcomes? We are not there yet.”

Removing zinc is not an option, as it is a part of 2 percent of the proteome, Liu said. Taking it out would “screw up the entire biological, physiological system,” he added.

Liu speculates that any future drug treatment would involve a relatively small dose at a specific time, although he recognized that any drug could have side effects.

In an uncertain funding climate in which the government is freezing some grants, Liu hopes that the financial support will continue through the duration of the grant.

“Our hope is that at the end of this grant, we can demonstrate” the mechanism of action for ZnPP and can find a reliable inhibitor, he said. “The next step would be to go to a clinical trial with an FDA-approved drug, and that would be fantastic.”

by -
0 627
Stony Brook Biomedical Engineer Gábor Balázsi, PhD. Photo by Lynn Spinnato

Gábor Balázsi, PhD, the Henry Laufer Professor of Physical and Quantitative Biology in the Laufer Center at Stony Brook University, has been named a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).

Balázsi took part in a formal induction ceremony in Arlington, Virginia, on March 31, for AIMBE’s 2025 Class of College Fellows, which includes 171 leading international scientists.

AIMBE Fellows are among the most distinguished medical and biological engineers. Fellows include four Nobel Prize laureates and 27 Presidential Medal of Science and/or Technology and Innovation awardees. Additionally, 233 Fellows have been inducted to the National Academy of Engineering, 120 into to the National Academy of Medicine, and 51 inducted to the National Academy of Sciences.

Balázsi, also a Professor in the Department of Biomedical Engineering and an affiliate member of the Stony Brook University Cancer Center, was nominated, reviewed, and elected by peers and members of the AIMBE College of Fellows “for pioneering contributions to apply engineering principles to design protein-level tuning synthetic gene circuits, and to identify mechanisms for their evolution.”

A professor and researcher at Stony Brook since 2014, Balázsi’s work centers on developing and evolving synthetic gene circuits. The core of the research is to enable a predictive, quantitative understanding and control of biological processes such as cellular decision-making and the survival and evolution of cell populations, such as in metastatic progression and chemoresistance in cancer.

His findings have led to published papers in approximately 50 journals, including Nature Communications, Nature Chemical Biology, PNAS, Cell, and Cell Chemical Biology.

The East Setauket resident is a member of the American Physical Society, the American Association for Cancer Research and the American Association for the Advancement of Science. 

AIMBE’s College of Fellows is comprised of almost 3,000 individuals who have made significant contributions to the medical and biological engineering community in academia, industry, government, and education that have transformed the world. Most AIMBE Fellows are from the United States but many hail from all over the word and represent more than 30 countries.

 

 

 

by -
0 1108
Mairead Carroll designed the most efficient bridge at this year's Bridge Building Competition. Photo by Kevin Coughlin/Brookhaven National Laboratory

And the results are in! Mairead Carroll, a senior from Northport High School, captured first place at the 2025 Bridge Building Competition hosted by the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory in Upton on March 14.

Students from 13 Long Island high schools followed a strict set of specifications to try to construct the most efficient model bridge out of lightweight basswood and glue.

The annual event shows high schoolers what it means to be an engineer in a fun, hands-on way and is one of many activities organized by Brookhaven Lab’s Office of Workforce Development and Science Education to cultivate the next generation of science, technology, engineering, and math professionals.

“Because many students spent the whole day at the Lab as a field trip, they were able to take some time to talk to our engineers and educational staff about their career journeys, making the experience about more than just building,” said Educational Programs Administrator Michele Darienzo. “Plus, we all had so much fun!”

Commack High School students Joshua Kim, left, Vincent D’Angelo, and Jordan Gleit earned three out of the four top spots awarded at the competition. Photo by Kevin Coughlin/Brookhaven National Laboratory

Carroll and second-place winner Vincent D’Angelo, a junior from Commack High School, qualify to bring their designs to the International Bridge Building Contest in Chicago, Illinois on April 26.

“Participating in the Brookhaven National Lab Bridge Competition was an incredible experience, and I’m so thankful for the opportunity to be part of it,” Carroll said. 

“It was a great chance to learn and grow as an aspiring civil engineer, and I’ve gained so much from the talented competitors I had the chance to meet. I’m excited to continue this journey and look forward to representing Northport at the International Bridge competition in Chicago,” she added.

Students and judges watched closely as Brookhaven Lab staff and volunteers tested 95 bridges under a crushing machine that slowly added more and more weight from above until the bridges broke or bent more than one inch. Bridges were ranked based on efficiency scores that are calculated from the load the bridge supports divided by the mass of the bridge — all in grams. The structures could not have a mass greater than 25 grams.

D’Angelo, who visited the Lab with classmates on competition day, said he focused on simplicity and keeping his bridge light. His fellow Commack High School students swept the contest’s remaining awards: junior Joshua Kim earned third place with a bridge that used trusses to maximize efficiency, and junior Jordan Gleit won an aesthetic award for bridge design thanks to a structure with lots of cross beams.

While bridge testing was underway, students toured the National Synchrotron Light Source II and Center for Functional Nanomaterials, two DOE Office of Science user facilities at Brookhaven with unique capabilities that draw scientists from all over the world to Long Island. Students met staff scientists and engineers and learned about the paths that led them to careers at BNL. 

Competitors further tested their engineering skills during an activity that challenged them to craft five increasingly difficult structures out of Geomag magnetic toys and earned Brookhaven Lab goodies if they were successful. Competition organizers also quizzed students with Brookhaven Lab and science trivia for chances to win more prizes.

by -
0 1093
Professor Michael Bender. Photo by John Griffin/Stony Brook University

Stony Brook University’s Gordon T. Taylor, Katherine B. Aubrecht, and Michael A. Bender were recently named 2024 American Association for the Advancement of Science (AAAS) Fellows.

The AAAS Fellows program was first established in 1874. To be considered as a Fellow, AAAS members must be nominated by the Steering Committee of their respective sections by three Fellows or the CEO of AAAS. Nominations are reviewed by the AAAS Council, which then votes on the nominations. To become an AAAS Fellow is a lifetime honor.

“This year’s class of Fellows are the embodiment of scientific excellence and service to our communities,” said Sudip S. Parikh, Ph.D., AAAS chief executive officer and executive publisher of the Science family of journals. “At a time when the future of the scientific enterprise in the U.S. and around the world is uncertain, their work demonstrates the value of sustained investment in science and engineering.”

“I warmly congratulate our newest AAAS fellows for this well-deserved and impressive recognition of their work and its importance to society,” said Carl W. Lejuez, executive vice president and provost. “We are proud that over the years about a dozen of our current faculty have been named AAAS fellows in a broad range of fields, including political science, psychology, creative writing and math and of course marine science and chemistry. Honors like these underscore our flagship status and Stony Brook’s value to our region and our nation.”

As AAAS Fellows, Taylor, Aubrecht, and Bender join a class of 471 scientists, engineers, and innovators. Together, they make up the ranks of distinguished scientists, engineers, and innovators who have been recognized for their contributions in the areas of academia, research, and science communications. Notable AAAS Fellows include Maria Mitchell, Steven Chu, Ellen Ochoa, Irwin M. Jacobs, Alan Alda, Mae Jemison, and Ayanna Howard.

Taylor, Aubrecht, and Bender will be recognized for their achievements at the Fellows Forum on June 7, an event held during the AAAS Annual Meeting, where they will be presented with a certificate and a blue and gold rosette.

Gordon T. Taylor

Professor Gordon Taylor. Photo by John Griffin/Stony Brook University

Gordon T. Taylor is a professor in the School of Marine and Atmospheric Sciences. He also serves as head of SoMAS’ Marine Sciences Division and as director of the NAno-Raman Molecular Imaging Laboratory (NARMIL). His alma mater is University of Southern California, where he earned his PhD in 1983.

“I am truly honored and humbled by this recognition,” said Professor Taylor. “I am indebted to all my talented, hard-working students and colleagues who were so instrumental in the achievement of my scientific goals. My sincere gratitude to AAAS for this acknowledgement. It means a great deal to me to join the ranks of AAAS Fellows.”

Professor Taylor is being honored for his distinguished contributions to furthering understanding of microbial mediation of marine biogeochemical processes, ecological interactions among microorganisms in marine food webs, and technical advances in Raman microspectrophotometry.

Katherine B. Aubrecht

Professor Katherine B. Aubrecht. Photo Courtesy of Finishing Touch Photo

Katherine B. Aubrecht is an associate professor in the College of Arts and Sciences department of Chemistry and in the School of Marine and Atmospheric Sciences division of Sustainability Studies. Her alma mater is Cornell University, where she earned her PhD in 1999.

“The American Association for the Advancement of Science (AAAS) works to advance science for the benefit of all by focusing on research, education, engagement with the public, and the use of science to inform policy,” said Professor Aubrecht. “I am grateful to be nominated and elected as an AAAS Fellow. I am also grateful for the opportunities at SBU for cross-disciplinary discussions and collaborations.”

Professor Aubrecht is being honored for her contributions to advancing chemistry education by incorporating green chemistry, sustainability, and systems thinking to foster more connected and relevant teaching and learning. She has worked with the American Chemical Society’s Green Chemistry Institute and Committee on Environment and Sustainability to further these objectives.

Michael A. Bender

Professor Michael Bender. Photo by John Griffin/Stony Brook University

Michael A. Bender is the John L. Hennessy Chaired Professor of Computer Science in the College of Engineering and Applied Sciences Department of Computer Science, where he runs the computer science honors program. He has won several awards, including an R&D 100 Award, a Test-of-Time Award, a Distinguished Paper Award, two Best Paper Awards, and five awards for graduate and undergraduate teaching. His alma mater is Harvard University, where he earned a PhD in 1998. Bender has also held Visiting Scientist positions at both MIT and Kings College London, and is a co-founder of the software company Tokutek, which was acquired by Percona in 2015.

“I am deeply honored to be recognized as an AAAS Fellow,” said Professor Bender. “I’m especially grateful for the collaborative efforts of many brilliant students, colleagues, and industry partners who have contributed to advancing our field.”

Professor Bender is being honored for his distinguished contributions to the foundations of data structures and their applications.

 

by -
0 804
Dr. John Inglis Photo from CSHL

By Daniel Dunaief

Evolution doesn’t just favor species that have adaptive advantages in a changing environment. It’s also relevant for businesses, as they move into new markets, and even to scientific publishing.

A preprint scientific publishing effort that started in 2013 at Cold Spring Harbor Laboratory with bioRxiv and expanded in 2019 with medRxiv is making changes that its creators believe positions it to grow while continuing to serve the scientific community.

BioRxiv and medRxiv are becoming an independent nonprofit, called openRxiv. The new format, which takes the preprint offerings outside the home of Cold Spring Harbor Laboratory, will create a product that is outside the realm of a single institution and that has transparent governance.

“We had an independent needs assessment done by a consulting company,” said Dr. John Inglis, Chair of the openRxiv Scientific and Medical Advisory Board. The governance needed to be “more community-oriented, with not just funders, but committees of working scientists.”

The Chan Zuckerberg Initiative, which has been the major funder for the preprint services, understood the benefits of transitioning to an independent non profit. They also wanted to “see a diversification of funding” from other sources and contributors, Inglis said.

Up until co-founders Inglis and Dr. Richard Sever, Chief Science and Strategy Officer at openRxiv created these two preprint services, most biological and medical scientific discoveries progressed through the slower pace of peer review publishing that helps them advance their fields while sharing their results.

Preprints, however, greatly accelerated that process by allowing researchers to display their work before peer review. While scientists might need to amend their findings by adding further studies, these preprints enable researchers to do the equivalent of presenting their research to a worldwide audience, the way scientists do at meetings.

The preprint servers are “like the biggest conference you’ve ever seen, with millions of people,” said Inglis.

A growing market 

In each month of the last quarter of 2024, bioRxiv recorded between 8 million and 9.7 million page views, with between 4.7 million and 6.8 million downloads, Inglis said. MedRxiv, meanwhile, had between 1.8 million and 1.9 million page views with a million downloads per month.

With more than 110 new articles per day last year, bioRxiv added 11 percent more original preprints last year. MedRxiv grew by 12 percent, adding 12,863 preprints last year, or about 35 new articles per day.

MedRxiv launched the year before the pandemic and quickly became the major channel of communication for pandemic-related preprints.

In 2020, when pandemic related coverage accounted for 80 percent of everything posted, medRxiv shared a total of 14,070 research pieces.

At this point, contributing authors have come from 190 countries. The most prolific contributors are the United States and the United Kingdom. With readers coming from around the world, openRxiv’s primary task is to convert some of the readers from other countries into contributors, Inglis said.

Search for a CEO

OpenRxiv creates opportunities for several executives.

Sever, who had been CSHL Press Assistant Director, will leave the lab to become the chief scientific and strategy officer for openRxiv.

At the same time, openRxiv, which has an annual budget of $3 million, has hired a recruiting firm to lead the search for its first Chief Executive Officer.

The new CEO will need to “believe in the mission, promise, potential and ambition of openRxiv,” said Inglis, as the CEO will be the “principal ambassador” for the effort.

The new leader will also need experience running a complex organization with various stakeholders and that has community engagement.

Inglis described the current employees, which includes eight full time staff, as “fantastically motivated.” He anticipates the new leader could be announced as soon as three or four months from now.

Expanded opportunities

The preprint servers has appealed to academic institutions directly for ongoing repeated support, through a membership model.

Indeed, preprint managers reached out on the 10th anniversary of bioRxiv and received backing from institutions that are listed on every bioRxiv and medRxiv preprint.

“We want to build on that, to reach out to more institutions,” said Inglis. He wants to have a “real dialog with them about what these servers mean to their faculty and how we can be useful in terms of their operations.”

Some academic institutions don’t always know which research studies are appearing on these servers.

OpenRxiv can give universities information for researchers who are posting their studies.

Additionally, these servers have been offering authors the chance to transfer their manuscripts to particular journals. At this point, openRxiv has connections with 45 publishers who oversee 380 journals.

Inglis said they charge a small fee to set that up and described this effort as the “germ” of a business model. He anticipates that openRxiv could provide more of these connections.

Professional pathways

Authors have the ability to correct or amend their work on these servers. The preprints encourage people to explain the changes, while discouraging too many corrections or changes for grammatical reasons. The record for revisions on bioRxiv or medRxiv is seven.

Inglis has heard from numerous researchers who are grateful to increase the visibility of their work and their careers in a timely way.

These non peer reviewed studies can help scientists move up the ladder, getting job offers from other institutions while they await publication in a journal.

Ongoing support

CSHL, BMJ Group and Yale School of Medicine remain key supporters of openRxiv.

“OpenRxiv is the natural evolution and progression of free and open access to scientific information,” Bruce Stillman, President and CEO of CSHL said in a statement. “BioRxiv and medRxiv have revolutionized the field of science and scientific publishing. The establishment of openRxiv will allow for continued innovation in how the latest scientific results are communicated.”

In the last few weeks, openRxiv had the first in a series of webinars they are mounting on their own behalf. They plan to offer them to institutions across the world and believe they are an effective way to engage with the world of international science.

OpenRxiv is in conversation with faculty at an institution in Japan about organizing a webinar and will reach out to institutions in India. Staff at openRxiv plan to expand the scope of this process by contacting authors in potential locations who have multiple articles on the servers.

The response from students is an “encouragement to do more,” said Inglis. “Having more people and more resources will allow us to ramp up educational development of what we’re doing.”

by -
0 1554
Dr. Sritha Rajupet. Photo from Stony Brook Medicine/Jeanne Neville

By Daniel Dunaief

While many people are fortunate enough to ignore Covid or try to put as much distance between themselves and the life altering pandemic, others, including people throughout Long Island, are battling long Covid symptoms that affect the quality of their lives.

Dr. Sritha Rajupet
 Photo from Stony Brook Medicine/Jeanne Neville

Sritha Rajupet, Director of the Post-Covid clinic at Stony Brook Medicine and Chair of Family, Population & Preventive Medicine, puts her triple-board certified experience to work in her efforts to provide relief and a greater understanding of various levels of symptoms from Covid including pain, brain fog, and discomfort.

Rajupet serves as co-Principal Investigator, along with Dr. Hal Skopicki, chief of cardiology and co-director of the Stony Brook Heart Institute, on a study called Recover-Autonomic.

This research, which uses two different types of repurposed treatments that have already received Food and Drug Administration approval in other contexts, is designed to help people who have an autonomic nervous system disorder called Postural Orthostatic Tachycardia Syndrome. People with this syndrome typically have a fast heart rate, dizziness or fatigue when they stand up from sitting down.

Stony Brook is contributing to a clinical trial for two different types of treatments, each of which has a control or placebo group. In one of the trials, patients receive Gamunex-C intravenous immunoglobulin. In the other, patients take Ivabradine by mouth.

Stony Brook has been enrolling patients in this study since the summer. The intravenous study is a nine-month trial.

Some improvements

Dawn Vogt, a 54-year-old Wading River resident, is enrolled in the intravenous trial.

While Vogt, who has been a patient of post Covid clinic since November of 2022, doesn’t know whether she’s getting the placebo or the intravenous treatment, she has been feeling better since entering the study.

Dawn Vogt in 2018.

The owner of a business called Office Solutions of Long Island, Vogt has been struggling for years with body aches, headaches, fever, stomach pain, fatigue and coughing.

“I’m definitely feeling better,” said Vogt, whose Covid fog can become so arduous on any given day that she struggles with her memory and her ability to put words together, as well as to engage in work that required multitasking.

“I’m a big puzzle person,” said Vogt. “[After Covid] I just couldn’t do it. It was and still is like torture.”

Still, Vogt, who was earning her undergraduate degree in women and gender studies at Stony Brook before she left to deal with the ongoing symptoms of Covid, feels as if several parts of her treatment, including the clinical trial, has improved her life.

Since her treatment that started during the summer, she has “definitely seen improvement,” Vogt said.

Dawn Vogt in 2023.

In addition to the clinical trial, Vogt, who had previously run a half marathon, received a pace maker, which also could be improving her health. “I’m starting to have more energy, instead of feeling exhausted all the time,” she said, and has seen a difference in her ability to sleep.

Vogt feels fortunate not only for the medical help she receives from Rajupet and the Stony Brook clinic, but also for the support of her partner Tessa Gibbons, an artist with whom Vogt developed a relationship and created a blended family in the years after Vogt’s husband died in 2018.

“My hope is that I can find a new normal and that I can become functional so that I can get back to doing some of what I love,” she said.

Vogt urges others not to give up. “If your doctors don’t believe you, find one who does,” she said. “My doctors at Stony Brook, including Dr. Rajupet and the whole team, are amazing. They listened, they are compassionate and they don’t ever say, ‘That’s crazy.’”

Indeed, in working with some of the over 1,500 unique patients who have come to Stony Brook Medicine’s post-Covid clinic, Rajupet said she “explores things together.” When her patients learn about something new that they find through their own research, she couples that knowledge with her own findings to develop a treatment plan that she hopes offers some comfort and relief.

Ongoing medical questions

Doctors engaged in the treatment of long Covid are eager to help people whose quality of life can and often is greatly diminished. 

People “haven’t been able to work, haven’t been able to do activities they enjoy whether that’s sports as a result of their fatigue or myalgia [a type of muscle pain]. Concentration may be affected, as people can’t read or perform their work-related activities,” said Rajupet.

At this point, long Covid disproportionately affects women.

During her family medicine residency, Rajupet learned about preventive medicine in public health. She worked with specific populations and completed an interdisciplinary women’s health research fellowship.

Her research background allowed her to couple her primary care experience with her women’s health background with a population approach to care.

The Stony Brook doctor would like to understand how many infections it takes to develop long Covid.

“For some, it’s that one infection, and for others, [long Covid] comes in on the third or fourth” time someone is battling the disease, Rajupet said.

She also hopes to explore the specific strains that might have triggered long Covid, and/ or whether something in a person’s health history affected the course of the disease.

Rajupet recognizes that the need for ongoing solutions and care for people who are managing with challenges that affect their quality of life remains high.

“There are still 17 million people affected by this,” she said. “We have to make sure we can care for them.”

As for Vogt, she is grateful for the support she receives at Stony Brook and for the chance to make improvements in a life she and Gibbons have been building.

Her hope is that “every day, week, month and even hour, I take one more breath towards being able to function as best as possible,” Vogt said. “My goal is to live the best life I can every day.”

by -
0 1464
Andrew Singer with students in a newly created makers space in the Engineering Building at SBU. Photo by Debra Scala Giokas/Stony Brook University

By Daniel Dunaief

Andrew Singer. Photo courtesy of SBU

Andrew Singer, the Dean of the College of Engineering and Applied Sciences (CEAS) at Stony Brook University, has bigger numbers in mind. For starters, he’d like to see CEAS increase in size, from 5,000 total students, including 3,500 undergraduates, to as many as 10,000 students.

“We are small as an institution compared to other institutions of our reputation in research,” said Singer, referring both to the overall population of the university and to the college he leads.

He believes growth at the CEAS could occur because there is “that much demand for a Stony Brook College of Engineering and Applied Sciences education right now.”

Singer, who joined Stony Brook in July of 2023, believes that state schools like Stony Brook provide an education that create life changing opportunities for people and their families. The lack of available housing on campus at this point is a rate limiting step in increasing the number of students who can attend.

Getting the word out

Singer, who came to Stony Brook after 25 years in the Electrical and Computer Engineering department at the University of Illinois, believes public universities have historically seen themselves as being local and serving the mission of the state, without needing to advertise.

“As public funding diminished, many public institutions realized they needed to tell the world that they were serving this tremendous mission and adding tremendous value to society,” Singer said.

Indeed, the late Chemistry Professor Paul Lauterbur helped invent the MRI machine, which has become such an important diagnostic tool in medicine. Lauterbur, who was a tenured professor at Stony Brook from 1963 to 1985, shared the Nobel Prize in Physiology or Medicine along with British Physicist Sir Peter Mansfield in 2003.

Singer also wants prospective students to know that John L. Hennessy, the former president of Stanford University and current chairman of Google’s parent company Alphabet, earned his Master’s and PhD degrees from Stony Brook.

“Telling our story not only can help to bring some of the world’s greatest educators and researchers to campus, but can also ensure that the resources needed to continue to build on our successes are available,” said Singer.

Finding funds

Additionally, the CEAS Dean believes professors in the college can diversify their sources of funding.

“One of the things I noticed at Stony Brook is that most of the research is funded through grants from the National Science Foundation, the National Institutes of Health and the Department of Energy,” he said. “That concentration of funding makes you vulnerable to changes in the funding cycle.”

Additionally, competition for funding from those agencies is extremely high.  Singer has been urging faculty at CEAS to seek funding from industrial sponsors.

“At the end of the day, what’s important is the scholarship you create,” he said.

Singer appreciates how his colleagues at Stony Brook are pursuing funds for larger interdepartmental funds.

Vice President for Research Kevin Gardner has “strong experience in building these larger portfolios of funding for faculty research,” Singer said. Gardner and Singer talk “often about ways we can continue to develop opportunities for faculty to go after new funding and present ideas to industry.”

Gardner described Singer as a “rock star” who has “great ideas” and is “super brilliant with tons of positive energy. He can move things and already has been moving things in a positive direction for CEAS.” 

Gardner believes engineering could and should be twice the size it is and suggested that Singer is “the guy who will get us there.”

Opportunities for growth

Singer appreciates the depth and breadth of faculty interests at the CEAS. “Our faculty are brilliant researchers, working at the forefront of many areas of importance to society, from information and energy systems, to human health and disease prevention, to clean water and security,” he said.  “With nine departments in the College of Engineering and Applied Sciences, it is difficult to find an area of science and engineering where our faculty are not having impact.”

Singer sees opportunities for growth in areas including artificial intelligence.

The university launched the AI Innovation Institute (AI3) in September of last year, which will expand the Institute for AI-driven Discovery and Innovation, which was established in 2018 from a department-level institute within the CEAS to the university-wide AI3, reporting to Provost Carl Lejuez. Steve Skiena, distinguished professor in the department of Computer Science, is serving as the interim director of AI3 while the university has been searching for an inaugural director.

The provost appreciates the efforts Singer has been making on behalf of the CEAS and the university. Singer is “good at thinking about the big things we need to focus on,” Lejuez said in an interview. Singer has “brought a leadership style that is consistent with the culture we’ve been trying to create over the past few years. We are partners with faculty, staff and students. We are including them not just at the end of decisions.”

Singer is also continuing to pursue his own scientific studies. His research interests include signal processing and communication systems. He has worked on underwater acoustics, where he studied underwater communication for the subsea industry. He has also worked in wireless communications for cellular and radio applications and in fiber optic communication systems.

Singer has two graduate students at Stony Brook and several students who are completing their work at Illinois. His students are working in areas related to audio signal processing, such as improving the performance of hearing aids and devices like noise-cancelling headphones, as well as in underwater acoustics.

Singer has had two companies emerge from research in his lab. He would like to continue to engage in innovation and entrepreneurship and help grow the entrepreneurial ecosystem at Stony Brook.

Quantum work

CEAS has invested in areas related to quantum communication.

In August 2024, Stony Brook was chosen to lead a project in the National Quantum Virtual Laboratory program. Funded by the National Science Foundation and led by Principal Investigator Eden Figueroa, Stony Brook Presidential Innovation Endowed Professor, the team is designing and implementing a 10-node quantum network connecting labs at Stony Brook, Brookhaven National Laboratory, Columbia University and Yale University.

Stony Brook held a workshop on Quantum Information Science and Communication systems in Manhattan that Figueroa led, in which some of the foremost experts in the field presented their work and discussed collaboration opportunities with Stony Brook, Singer explained.

Stony Brook has its “local and global strengths.” Singer wants to focus on building on those areas and to have SBU becoming well known to students and faculty as a destination of choice.

123...72Next Page 1 of 72
TBR News Media is your local news and entertainment website.
We provide you with the latest breaking news and information for your community.
Contact us: [email protected]

Most Viewed

©